| 1.41 0.17 (13.71%) | 11-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.77 |
1-year : | 2.07 |
| Resists | First : | 1.51 |
Second : | 1.77 |
| Pivot price | 1.22 |
|||
| Supports | First : | 1.28 |
Second : | 1.13 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.24 |
| MA(100) : | 1.59 |
MA(250) : | 2.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 34.6 |
| RSI | RSI(14): 58.2 |
|||
| 52-week | High : | 21.95 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MBIO ] has closed It is unclear right now based on current values. 68% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.28 - 1.28 | 1.28 - 1.29 |
| Low: | 1.17 - 1.17 | 1.17 - 1.18 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Wed, 09 Jul 2025
Mustang Bio’s Stock Soars: What’s Driving the Surge? - timothysykes.com
Wed, 09 Jul 2025
Mustang Bio Receives FDA Orphan Drug Designation - TipRanks
Mon, 07 Jul 2025
Biotech Stock Analysis: MBIO Soars after FDA Grants Orphan Drug Designation - Markets.com
Mon, 07 Jul 2025
Mustang Bio rises after FDA orphan drug status for MB-101 - Seeking Alpha
Mon, 07 Jul 2025
Mustang Bio (MBIO) Soars as FDA Grants Orphan Drug Status - GuruFocus
Mon, 07 Jul 2025
Mustang Bio stock soars after FDA grants orphan drug designation - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 61 (K) |
| Shares Short P.Month | 61 (K) |
| EPS | -6.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -8.2 % |
| Return on Equity (ttm) | -418.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|